Article

Flavoprotein autofluorescence may be early indicator of eye disease, say researchers

A new device used to evaluate the eye for disease may warn physicians earlier than before, especially when linked to diabetes.

Ann Arbor, MI-A new device used to evaluate the eye for disease may warn physicians earlier than before, especially when linked to diabetes. The device captures images of the eye that reveal metabolic stress and tissue damage, even before the first signs of the disease appear, said a team of researchers at the University of Michigan.

Flavoprotein autofluorescence (FA)-thought to be a reliable indicator of eye trouble-is measured using this technology.

"The concept behind measuring FA in the retina is to determine whether there's a metabolic dysfunction in the retinal tissue," explained lead researcher Victor M. Elner, MD, PhD, a professor in the university's Department of Ophthalmology and Visual Sciences.

People with diabetes had significantly higher levels of FA compared with nondiabetics, the researchers report. "The diabetics demonstrated consistently abnormal metabolism when compared with the control individuals without disease," Dr. Elner said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.